Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Interleukin 33 Regulation for Cancer Prevention in Chronic Inflammation

Award Number: R01CA283214
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2024
PERIOD OF PERFORMANCE END DATE: 03/31/2029

Group Awards By:

View Award Description

Interleukin 33 Regulation for Cancer Prevention in Chronic Inflammation - Project Summary/Abstract The overarching goal of the proposed research is to elucidate the initiating mechanisms in the development of cancer-prone chronic inflammation for cancer prevention and therapy. Chronic inflammatory diseases, such as chronic dermatitis, pancreatitis, colitis and hepatitis, are major risk factors for cancer. In addition, a tumor- promoting immune environment, which resembles chronic inflammation, is a key driver of cancer development across the majority of cancer types. By studying the mediators of the transition from acute to chronic inflammation, we have demonstrated that interleukin (IL)-33 cytokine is a key initiator of chronic inflammation that eventually leads to cancer development in the skin, colon and pancreas. Importantly, we have recently discovered that the nuclear function of IL-33 within the epithelial cells plays an essential role in cancer development in chronic skin and pancreas inflammation. To develop an effective strategy to suppress cancer- prone chronic inflammation, we will focus on the mechanism that blocks the initiating steps in the development of a cancer-prone chronic inflammation. Founded on our innovative discovery that IL-33 is an essential initiator of cancer-prone chronic inflammation, we aim to determine the mechanism of IL-33 induction in tissues exposed to inflammatory insults and to develop a novel therapeutic approach to inhibit IL-33 expression for cancer prevention and therapy. To accomplish this, we will use novel mouse models and clinical samples to (1) determine the mechanism of IL-33 induction in chronic inflammation triggered by chemical agents, (2) investigate the role of IL-33 in cancer-prone chronic inflammation associated with a viral infection, and (3) study inhibitor of IL-33 that can block chronic inflammation and the subsequent cancer development. The outcomes of our research will establish a fundamental pathway to suppress chronic inflammation-associated cancer and provide the means to prevent cancer progression and recurrence.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $604,063 )
2026	2026	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Cancer Biology Research	000	3	3/23/2026	NON-COMPETING CONTINUATION	$604,063
														Subtotal = $604,063

Issue Date FY: 2025 ( Subtotal = $604,063 )
2025	2025	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Cancer Biology Research	001	2	5/22/2025	NON-COMPETING CONTINUATION	$60,405
2025	2025	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Cancer Biology Research	000	2	3/14/2025	NON-COMPETING CONTINUATION	$543,658
														Subtotal = $604,063

Issue Date FY: 2024 ( Subtotal = $604,063 )
2024	2024	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Cancer Biology Research	000	1	3/28/2024	NEW	$604,063
														Subtotal = $604,063

Grand Total All Awards = $1,812,189

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Interleukin 33 Regulation for Cancer Prevention in Chronic Inflammation

Award Number: R01CA283214

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2024

PERIOD OF PERFORMANCE END DATE: 03/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer